FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111562236> ?p ?o ?g. }

• W2111562236 endingPage "1507.e13" @default.
• W2111562236 startingPage "1497" @default.
• W2111562236 abstract "Background & AimsLiver X receptors (LXRs) are transcriptional regulators of cholesterol metabolism, controlling cholesterol flow into cells, catabolism, and efflux. Cholesterol controls cell proliferation; disruptions in cholesterol metabolism have been associated with the development of colon cancer. We investigated whether expression of activated LXR protects against intestinal tumorigenesis in mice.MethodsWe analyzed the development of colon cancer in mice that express a constitutive active form of LXRα only in the intestinal epithelium, under the control of villin promoter (iVP16LXRα). These mice were crossed with adenomatous polyposis coli (Apc)min/+ mice, or given azoxymethane followed by dextran sodium sulfate, to assess intestinal tumor formation. We also assessed proliferation and apoptosis of a human colorectal cancer cell line (HT29) transfected with an adenoviral vector that expressed Ad VP16hLXRα, compared with cells expressing AdVP16 (control), and their ability to form xenograft tumors in mice. HT29 cells also were incubated with the LXR ligand GW3965.ResultsIn human colorectal cancer cells, ligand-induced activation of LXR or transfection with Ad VP16hLXRα blocked the G1 phase, increased caspase-dependent apoptosis, and slowed growth of xenograft tumors in mice. iVP16LXRα mice formed fewer, smaller tumors than VP16 (control) mice after administration of azoxymethane and dextran sodium sulfate. APCmin/+/iVP16LXRα mice also developed fewer, smaller intestinal tumors than APCmin/+/iVP16 mice. Gene expression analysis indicated that activation of LXRα affected lipid metabolic networks and increased cholesterol efflux in the intestine.ConclusionsExpression of activated LXRα blocks proliferation of human colorectal cancer cells and slows the growth of xenograft tumors in mice. It also reduces intestinal tumor formation after administration of chemical carcinogens, and in Apcmin/+ mice. LXR agonists therefore might be developed as therapeutic treatments for colorectal cancer. Liver X receptors (LXRs) are transcriptional regulators of cholesterol metabolism, controlling cholesterol flow into cells, catabolism, and efflux. Cholesterol controls cell proliferation; disruptions in cholesterol metabolism have been associated with the development of colon cancer. We investigated whether expression of activated LXR protects against intestinal tumorigenesis in mice. We analyzed the development of colon cancer in mice that express a constitutive active form of LXRα only in the intestinal epithelium, under the control of villin promoter (iVP16LXRα). These mice were crossed with adenomatous polyposis coli (Apc)min/+ mice, or given azoxymethane followed by dextran sodium sulfate, to assess intestinal tumor formation. We also assessed proliferation and apoptosis of a human colorectal cancer cell line (HT29) transfected with an adenoviral vector that expressed Ad VP16hLXRα, compared with cells expressing AdVP16 (control), and their ability to form xenograft tumors in mice. HT29 cells also were incubated with the LXR ligand GW3965. In human colorectal cancer cells, ligand-induced activation of LXR or transfection with Ad VP16hLXRα blocked the G1 phase, increased caspase-dependent apoptosis, and slowed growth of xenograft tumors in mice. iVP16LXRα mice formed fewer, smaller tumors than VP16 (control) mice after administration of azoxymethane and dextran sodium sulfate. APCmin/+/iVP16LXRα mice also developed fewer, smaller intestinal tumors than APCmin/+/iVP16 mice. Gene expression analysis indicated that activation of LXRα affected lipid metabolic networks and increased cholesterol efflux in the intestine. Expression of activated LXRα blocks proliferation of human colorectal cancer cells and slows the growth of xenograft tumors in mice. It also reduces intestinal tumor formation after administration of chemical carcinogens, and in Apcmin/+ mice. LXR agonists therefore might be developed as therapeutic treatments for colorectal cancer." @default.
• W2111562236 created "2016-06-24" @default.
• W2111562236 creator A5005244612 @default.
• W2111562236 creator A5006233820 @default.
• W2111562236 creator A5028922467 @default.
• W2111562236 creator A5030773051 @default.
• W2111562236 creator A5031384463 @default.
• W2111562236 creator A5035321510 @default.
• W2111562236 creator A5038043231 @default.
• W2111562236 creator A5041761706 @default.
• W2111562236 creator A5046657664 @default.
• W2111562236 creator A5066679687 @default.
• W2111562236 creator A5067186261 @default.
• W2111562236 creator A5073283234 @default.
• W2111562236 date "2013-06-01" @default.
• W2111562236 modified "2023-10-16" @default.
• W2111562236 title "Liver X Receptors Inhibit Proliferation of Human Colorectal Cancer Cells and Growth of Intestinal Tumors in Mice" @default.
• W2111562236 cites W1486963290 @default.
• W2111562236 cites W1574122095 @default.
• W2111562236 cites W1860242155 @default.
• W2111562236 cites W1996168740 @default.
• W2111562236 cites W2001079924 @default.
• W2111562236 cites W2001258296 @default.
• W2111562236 cites W2002404925 @default.
• W2111562236 cites W2009440060 @default.
• W2111562236 cites W2011910303 @default.
• W2111562236 cites W2014000186 @default.
• W2111562236 cites W2020969330 @default.
• W2111562236 cites W2022493303 @default.
• W2111562236 cites W2027585225 @default.
• W2111562236 cites W2037076407 @default.
• W2111562236 cites W2052579476 @default.
• W2111562236 cites W2056971612 @default.
• W2111562236 cites W2057830803 @default.
• W2111562236 cites W2059813946 @default.
• W2111562236 cites W2071288722 @default.
• W2111562236 cites W2074787458 @default.
• W2111562236 cites W2078323658 @default.
• W2111562236 cites W2089987351 @default.
• W2111562236 cites W2100396630 @default.
• W2111562236 cites W2100481402 @default.
• W2111562236 cites W2102628825 @default.
• W2111562236 cites W2104016841 @default.
• W2111562236 cites W2104450983 @default.
• W2111562236 cites W2104526266 @default.
• W2111562236 cites W2105052532 @default.
• W2111562236 cites W2111099974 @default.
• W2111562236 cites W2115955355 @default.
• W2111562236 cites W2128403373 @default.
• W2111562236 cites W2142402369 @default.
• W2111562236 cites W2153229802 @default.
• W2111562236 cites W2155385401 @default.
• W2111562236 cites W2156048227 @default.
• W2111562236 cites W2172256092 @default.
• W2111562236 doi "https://doi.org/10.1053/j.gastro.2013.02.005" @default.
• W2111562236 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23419360" @default.
• W2111562236 hasPublicationYear "2013" @default.
• W2111562236 type Work @default.
• W2111562236 sameAs 2111562236 @default.
• W2111562236 citedByCount "83" @default.
• W2111562236 countsByYear W21115622362013 @default.
• W2111562236 countsByYear W21115622362014 @default.
• W2111562236 countsByYear W21115622362015 @default.
• W2111562236 countsByYear W21115622362016 @default.
• W2111562236 countsByYear W21115622362017 @default.
• W2111562236 countsByYear W21115622362018 @default.
• W2111562236 countsByYear W21115622362019 @default.
• W2111562236 countsByYear W21115622362020 @default.
• W2111562236 countsByYear W21115622362021 @default.
• W2111562236 countsByYear W21115622362022 @default.
• W2111562236 countsByYear W21115622362023 @default.
• W2111562236 crossrefType "journal-article" @default.
• W2111562236 hasAuthorship W2111562236A5005244612 @default.
• W2111562236 hasAuthorship W2111562236A5006233820 @default.
• W2111562236 hasAuthorship W2111562236A5028922467 @default.
• W2111562236 hasAuthorship W2111562236A5030773051 @default.
• W2111562236 hasAuthorship W2111562236A5031384463 @default.
• W2111562236 hasAuthorship W2111562236A5035321510 @default.
• W2111562236 hasAuthorship W2111562236A5038043231 @default.
• W2111562236 hasAuthorship W2111562236A5041761706 @default.
• W2111562236 hasAuthorship W2111562236A5046657664 @default.
• W2111562236 hasAuthorship W2111562236A5066679687 @default.
• W2111562236 hasAuthorship W2111562236A5067186261 @default.
• W2111562236 hasAuthorship W2111562236A5073283234 @default.
• W2111562236 hasBestOaLocation W21115622361 @default.
• W2111562236 hasConcept C104317684 @default.
• W2111562236 hasConcept C121608353 @default.
• W2111562236 hasConcept C126322002 @default.
• W2111562236 hasConcept C134018914 @default.
• W2111562236 hasConcept C149011108 @default.
• W2111562236 hasConcept C167400880 @default.
• W2111562236 hasConcept C190283241 @default.
• W2111562236 hasConcept C2777704780 @default.
• W2111562236 hasConcept C2778452354 @default.
• W2111562236 hasConcept C502942594 @default.
• W2111562236 hasConcept C526805850 @default.
• W2111562236 hasConcept C54009773 @default.
• W2111562236 hasConcept C54355233 @default.

• next